[1] Teoh L, Moses G, McCullough MJ. A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions. Part 2[J]. J Oral Pathol Med, 2019, 48(7):637-646.
[2] Carrozzo M, Porter S, Mercadante V, et al. Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorhythms, prognosis, management strategies[J]. Periodontol 2000, 2019, 80(1):105-125.
[3] Shazib MA, Woo SB, Sroussi H, et al. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series[J]. Oral Dis, 2020, 26(2):325-333.
[4] Sibaud V, Eid C, Belum VR, et al. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings[J]. J Eur Acad Dermatol Venereol, 2017, 31(10):e464-e469.
[5] Cheng YS, Gould A, Kurago Z, et al. Diagnosis of oral lichen planus: a position paper of the American Academy of Oral and Maxillofacial Pathology[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(3):332-354.
[6] Villa A, Kuten-Shorrer M. Pathogenesis of oral toxicities associated with targeted therapy and immunotherapy[J]. Int J Mol Sci, 2023, 24(9):8188.
[7] Xie DY, Zhu K, Ren ZG, et al. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2023, 12(2):216-228.
[8] Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8):525-543.
[9] Asan MF, Castelino RL, Babu SG, et al. Oral immune-related adverse events-current concepts and their management[J]. Asia Pac J Oncol Nurs, 2021, 8(6):604-609.
[10] Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails[J]. Am J Clin Dermatol, 2018, 19(Suppl 1):31-39.
[11] Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events[J]. J Am Acad Dermatol, 2020, 83(5):1255-1268.
[12] Elad S, Yarom N, Zadik Y, et al. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies[J]. CA Cancer J Clin, 2022, 72(1):57-77.
[13] Shah N, Cohen L, Seminario-Vidal L. Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review[J]. J Am Acad Dermatol, 2020, 83(5):1493-1498.
[14] Duan S, Zhang X, Wang F, et al. Coexistence of oral mucous membrane pemphigoid and lichenoid drug reaction: a case of toripalimab-triggered and pembrolizumab-aggravated oral adverse events[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021, 132(3):e86-e91.
[15] Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab(Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook[J]. Cancer Treat Rev, 2020, 86:102017.
[16] Ruiz-Casado A, Gutiérrez L, Sánchez A, et al. Geographic tongue induced by angiogenesis inhibitors[J]. Rev Clin Esp(Barc), 2018, 218(9):501-502.
[17] Economopoulou P, Nicolatou-Galitis O, Kotsantis I, et al. Nivolumab-related lichen planus of the lip in a patient with head and neck cancer[J]. Oral Oncol, 2020, 104:104623.
[18] Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2018, 36(28):2872-2878.
[19] Rapoport BL, van Eeden R, Sibaud V, et al. Supportive care for patients undergoing immunotherapy[J]. Support Care Cancer, 2017, 25(10):3017-3030. |
